Belgian-based biopharmaceutical company Cardio3 Biosciences has unveiled a €19m ($24.4) funding round that saw previous investors inject €7m in new equity alongside the conversion of €12m in existing convertible loans. The formal capital increase was approved at a shareholder meeting and is expected to complete by the end of May 2013. The fresh capital will allow…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
